Opinion|Videos|February 10, 2025
Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Advertisement
Video content above is prompted by the following:
- How do the treatment options evolve as a child ages?
- FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
- How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
- Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
ACIP votes to update hepatitis B vaccine recommendation for infants
2
New analysis highlights nirsevimab as most impactful RSV prevention strategy for infants
3
Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates
4
Christine Eng, MD, on addressing barriers to exome and genome sequencing in clinical practice
5
